Nucleic Acid Amplification Testing Market To Reach $19.2 Billion By 2030

Nucleic Acid Amplification Testing Market Growth & Trends

The global nucleic acid amplification testing market size is expected to reach USD 19.2 billion by 2030, registering a CAGR of 12.2% from 2023 to 2030, according to a new report by Grand View Research, Inc. Rising awareness regarding early detection of chronic and infectious diseases, and emerging technological advancements in PCR technology are the factors expected to significantly drive the market growth. In addition, the global rise in the prevalence of infectious diseases such as influenza, hepatitis, and sexually transmitted infections is anticipated to increase the demand for nucleic acid amplification testing and positively affect market growth.

Nucleic acid amplification testing has witnessed a high amount of investment in recent years due to its applicability to diagnose a variety of disease conditions, including life-threatening conditions such as cancer. For instance, the development of Cepheid’s Gene Xpert technology involved a total public investment of over USD 252.0 million, including grants of more than USD 56.0 million from the National Institutes of Health, and around USD 73.0 million from other U.S. government departments.

Moreover, the high efficiency and accuracy of nucleic acid amplification testing have led to an increasing preference for the technique over traditional diagnostic options, such as culture-based identification. These attributes are boosting the growth of nucleic acid amplification testing technologies.

COVID-19 has increased demand for rapid and accurate testing methods, including nucleic acid amplification testing, for the detection of the SARS-CoV-2 virus. Key players involved in the market have developed new product offerings, such as isothermal nucleic acid amplification technology-based tests, to meet the high demand for rapid and point-of-care testing.

For instance, in March 2020, Abbott Laboratories received Emergency Use Authorization (EUA) for its Abbott ID NOW COVID-19 test which can deliver positive results within five minutes and negative results within 13 minutes. Such strategic initiatives fueled by the pandemic are expected to boost market growth in the near future.

 Request a free sample copy or view report summary: Nucleic Acid Amplification Testing Market Report

Nucleic Acid Amplification Testing Market Report Highlights

• Polymerase Chain Reaction (PCR) tests held the largest share of 66.7% in 2022 as the testing type allows for the high accuracy and multiplexing capabilities for the detection of a broad range of pathogens

• By application, infectious diseases accounted for the largest share of 46.4% in 2022. The rising prevalence of the infectious disease globally and efficient testing alternatives offered by nucleic acid amplification techniques are driving the segment

• North America held the largest share of 37.1% in 2022, due to the presence of an established healthcare sector and key players such as Abbott Laboratories; Illumina, Inc.; Bio-Rad Laboratories, Inc., and others in the region

• Central and reference laboratories end-use segment dominated the market in 2022 with a market share of 41.9% in 2022 due to the increasing healthcare investments and rising adoption of nucleic acid amplification tests for early disease diagnosis

Nucleic Acid Amplification Testing Market Segmentation

Grand View Research has segmented the global nucleic acid amplification testing market based on the type, application, end-use, and region:

Nucleic Acid Amplification Testing Type Outlook (Revenue, USD Million, 2018 - 2030)

• Polymerase Chain Reaction (PCR) Tests

• Isothermal Nucleic Acid Amplification Technology (INAAT) Tests

• Ligase Chain Reaction (LCR) Tests

Nucleic Acid Amplification Testing Application Outlook (Revenue, USD Million, 2018 - 2030)

• Infectious Disease Testing          

  • COVID-19 Testing

  • Mosquito Borne Disease Testing

  • Influenza testing

  • Sexually Transmitted Infections Testing

  • Hepatitis Testing

  • Tuberculosis Testing

  • Others

• Oncology Testing

• Genetic & Mitochondrial Disease Testing 

• Others     

Nucleic Acid Amplification Testing End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Central and Reference Laboratories

• Others

Nucleic Acid Amplification Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Nucleic Acid Amplification Testing Market

• F. Hoffmann-La Roche Ltd

• Becton, Dickinson and Company

• Danaher Corporation

• Abbott Laboratories

• Illumina, Inc.

• Siemens Healthineers

• bioMérieux SA

• Novartis AG

• Bio-Rad Laboratories, Inc.

• Seegene Inc.